Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Levine James E.Ownership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,008Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Kabbinavar FairoozOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,008Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Smeal TodOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,008Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Erlander MarkOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:510,000Price:--
-
Dec 19, 2023 (filed on Dec 19, 2023)Insider Name:Pace Gary WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$1.37
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Markin Rodney SOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Armitage James OOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:White LaleOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Pace Gary WOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Mohindru ManiOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
Filings by filing date
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Levine James E.Ownership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,008Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Kabbinavar FairoozOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,008Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Smeal TodOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,008Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Erlander MarkOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:510,000Price:--
-
Dec 19, 2023 (filed on Dec 19, 2023)Insider Name:Pace Gary WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$1.37
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Markin Rodney SOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Armitage James OOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:White LaleOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Pace Gary WOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Mohindru ManiOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,700Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 11055 Flintkote Ave SAN DIEGO CA 92121-1220 |
Tel: | N/A |
Website: | https://cardiffoncology.com |
IR: | See website |
Key People | ||
Mark Erlander Chief Executive Officer, Director | James E. Levine Chief Financial Officer | Vicki Kelemen Chief Operating Officer |
Tod Smeal Chief Scientific Officer | Fairooz Kabbinavar Chief Medical Officer |
Business Overview |
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cardiff Oncology Inc revenues increased 26% to $488K. Net loss applicable to common stockholders increased 7% to $41.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development Expense increase of 15% to $23.7M (expense), Salaries and staff costs increase of 47% to $5.9M (expense). |
Employees: | 31 as of Feb 22, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $119.52M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.49M as of Dec 31, 2023 |
EBITDA (TTM): | -$45.01M as of Dec 31, 2023 |
Net annual income (TTM): | -$41.47M as of Dec 31, 2023 |
Free cash flow (TTM): | -$31.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 44,677,169 as of Feb 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |